Highest-materiality recent filing
Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson elected as Class I directors to serve until 2029 annual meeting.
Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M
Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024
FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY
2025 total revenue >$340M, above guided range of $327-335M.
Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test
Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
Castle Biosciences adopts amended bylaws with changes to meeting procedures and governance
Board adopted amended and restated bylaws effective August 5, 2025, modifying quorum, advance notice, and proxy rules.
Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY
Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
Castle Biosciences shareholders approve officer exculpation charter amendment; re-elect directors
Stockholders approved amendment to certificate of incorporation to limit officer liability per Delaware law, effective May 22, 2025.
Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse
Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M
Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M
Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
Daniel M. Bradbury elected as Class II director with 15.95M for, 5.28M withhold; Rodney Cotton with 21.11M for, 117K withhold.
Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M
Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
Castle Biosciences secures $35M SVB loan facility; appoints Rodney Cotton to board
Entered Loan Agreement with Silicon Valley Bank for $10M drawn, $25M additional available.
Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M
Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%
Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
On March 26, 2024, Mara G. Aspinall notified the Company that she will not to stand for re-election to the board of directors (the “Board”) of the Company at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
On March 26, 2024, following the recommendation of the nominating and corporate governance committee of the Board, the Board increased the size of the Board from eight to nine members and appointed Rodney Cotton to serve as a Class II director with a term ending at the 2024 Annual Meeting.
Max materiality 0.85 · Median 0.75 · Most common event earnings